November 30, 2006
DxS, Manchester, UK, has been awarded a Biotechnology Project of the Year award for its Epidermal Growth Factor Receptor Mutation Test Kit.
DxS has used its scientific and commercial resources to develop the first tumor mutation analysis kit to identify patients who will respond well to certain lung cancer therapies. The oncogene assay can detect the 29 most common somatic mutations in the epidermal growth factor receptor gene, identifying mutations that are not visible by sequencing techniques.
The award, sponsored by the Manchester-based law firm Pannone LLP, was presented by the Northwest Regional Development Agency’s biotechnology cluster support group, Bionow, at its annual awards ceremony in order to showcase the best biotechnology in the region.
